Company Filing History:
Years Active: 2019
Title: Sriranganathan Nammalwar: Innovator in Multivalent Vaccine Development
Introduction
Sriranganathan Nammalwar is a notable inventor based in Blacksburg, VA (US). He has made significant contributions to the field of vaccine development, particularly in creating innovative solutions for mycobacterial infections. His work is characterized by a commitment to advancing public health through scientific research and innovation.
Latest Patents
Nammalwar holds a patent for a multivalent vaccine designed for protection against mycobacterial infections. The patent, titled "Multivalent vaccine for protection against mycobacterial infections and methods of using the same," describes a vaccine that expresses at least one heterologous antigen. This environmentally safe bivalent vaccine aims to provide protection against infections simultaneously. The multivalent vaccine comprises a strain transformed with a vector that expresses at least one antigen, which is codon optimized for the strain. Specifically, the strain is RB51 leuB, and the antigens include Ag85B, Rv2660c, and ESAT6. Nammalwar's innovative approach has the potential to significantly impact the treatment and prevention of mycobacterial diseases.
Career Highlights
Sriranganathan Nammalwar is associated with Virginia Tech Intellectual Properties, Inc., where he continues to engage in groundbreaking research. His dedication to innovation in vaccine technology has positioned him as a key figure in the field. With a focus on developing effective solutions for complex health challenges, Nammalwar's work exemplifies the intersection of science and public health.
Collaborations
Throughout his career, Nammalwar has collaborated with talented individuals such as Hamzeh Al Qublan and Garrett Smith. These collaborations have fostered a dynamic research environment, enabling the exploration of new ideas and the advancement of vaccine technology.
Conclusion
Sriranganathan Nammalwar's contributions to the field of vaccine development, particularly through his patent for a multivalent vaccine, highlight his role as an innovator in addressing mycobacterial infections. His work at Virginia Tech Intellectual Properties, Inc. and collaborations with fellow researchers underscore the importance of teamwork in scientific advancement.